In the past week, the United States market has experienced a 3.5% increase and boasts a remarkable 31% rise over the last year, with earnings projected to grow by 16% annually. In such an environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company's operations and potential for promising growth.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 13% | 53.5% |
| Precigen (PGEN) | 11.6% | 68.4% |
| Karman Holdings (KRMN) | 17.2% | 53.2% |
| GBank Financial Holdings (GBFH) | 27.3% | 42.2% |
| Enovix (ENVX) | 11.3% | 41.1% |
| Clene (CLNN) | 13.2% | 62.2% |
| Caledonia Mining (CMCL) | 14.3% | 28.4% |
| Better Home & Finance Holding (BETR) | 20.6% | 97.4% |
| Astera Labs (ALAB) | 10.5% | 29.0% |
| AppLovin (APP) | 27.3% | 21.3% |
Underneath we present a selection of stocks filtered out by our screen.
ImmunityBio (IBRX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: ImmunityBio, Inc. is a biotechnology company that innovates, develops, and commercializes next-generation immunotherapies aimed at activating the immune system for durable protection against cancer and infectious diseases, with a market cap of approximately $7.54 billion.
Operations: The company's revenue primarily comes from its efforts in developing next-generation therapies, amounting to $113.29 million.
Insider Ownership: 28.6%
Earnings Growth Forecast: 63.3% p.a.
ImmunityBio, a growth company with high insider ownership, is projected to experience robust revenue growth of 50.9% annually and anticipates profitability within three years. Despite a volatile share price and recent shareholder dilution, the stock trades significantly below its estimated fair value. The company faces legal challenges due to alleged misleading statements about its product Anktiva's capabilities. Meanwhile, ImmunityBio progresses in clinical trials for bladder cancer treatments and expands globally despite financial losses.
- Click here to discover the nuances of ImmunityBio with our detailed analytical future growth report.
- Our valuation report unveils the possibility ImmunityBio's shares may be trading at a premium.
Samsara (IOT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Samsara Inc. offers solutions that link physical operations data to its connected operations platform globally, with a market cap of $18.73 billion.
Operations: The company generates revenue primarily from its Software & Programming segment, amounting to $1.62 billion.
Insider Ownership: 35.6%
Earnings Growth Forecast: 73.9% p.a.
Samsara has demonstrated strong growth potential, with revenue increasing to US$1.62 billion in the past year and a forecasted rise to nearly US$2 billion in fiscal 2027. The company is enhancing its offerings with AI-driven solutions like Samsara Coach and Asset Tag XS, backed by insights from its newly established Customer Advisory Board. Despite recent insider selling, no substantial buying occurred over the last three months, indicating mixed insider sentiment amid ongoing product innovation and market expansion efforts.
- Delve into the full analysis future growth report here for a deeper understanding of Samsara.
- In light of our recent valuation report, it seems possible that Samsara is trading beyond its estimated value.
XPeng (XPEV)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: XPeng Inc. is a company that designs, develops, manufactures, and markets smart electric vehicles in China with a market cap of approximately $16.92 billion.
Operations: The company's revenue primarily comes from its smart electric vehicle segment, generating approximately CN¥76.72 billion.
Insider Ownership: 20.9%
Earnings Growth Forecast: 46.7% p.a.
XPeng is expanding globally, entering the Mexican market with plans to launch new electric models by 2027. Despite a forecasted revenue growth of 15.6% annually, which surpasses the US market average, XPeng's profitability is expected in three years. Recent announcements revealed significant delivery increases and improved financial results for Q4 2025. However, insider trading activity remains unreported over recent months, suggesting stable internal confidence amidst strategic advancements and technological innovations in AI-driven mobility solutions.
- Unlock comprehensive insights into our analysis of XPeng stock in this growth report.
- Insights from our recent valuation report point to the potential overvaluation of XPeng shares in the market.
Summing It All Up
- Get an in-depth perspective on all 205 Fast Growing US Companies With High Insider Ownership by using our screener here.
- Ready To Venture Into Other Investment Styles? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 26 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com